| abstract |
REFERS TO COMPOUNDS DERIVED FROM INDOLE OF FORMULA (I) WHERE X1 AND X2 ARE EACH C O N; Y1 IS ARYL OR -C (R2) (R3) (R4), WHERE R2 IS H, -O-ALKYL (C1-C6), -OH, -CN, AMONG OTHERS; R3 AND R4 ARE EACH H, ALKYL (C1-C6), HALOALKYL (C1-C6), ARYL, AMONG OTHERS; Y2 AND Z ARE EACH H OR ALKYL (C1-C6); R1a AND R1b ARE EACH H, HALOGEN, -O-ALKYL (C1-C6), -O-HALOALKYL (C1-C6), AMONG OTHERS; THE DOTTED LINES ARE A SINGLE OR DOUBLE LINK. THE PREFERRED COMPOUNDS ARE: ACID [7- (4-BENZYL- [1,2,3] TRIAZOL-1-IL) -6,7,8,9-TETRAHYDROPYRIDO [1,2-a] INDOL-10-IL] - ACETIC; [3- (5-BENZYL- [1,2,3] TRIAZOL-1-IL) -1,2,3,4-TETRAHYDRO-CARBAZOL-9-IL] -ACETIC; THIRD-BUTYL ACID ESTER 4- [3- (10-CARBOXIMETHYL-6,7,8,9-TETRAHYDROPYRIDO [1,2-a] INDOL-7-IL) -3H- [1,2,3] TRIAZOL- 4-IL] -PIPERIDINE-1-CARBOXYL; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT ALSO CONTAINS MONTELUKAST, PRANLUKAST OR ZAFIRLUKAST. THESE COMPOUNDS ARE ANTAGONISTS OF THE CHEMOATRAYING RECEPTOR EXPRESSED IN TH2 CELLS (CRTH2), BEING USEFUL IN THE TREATMENT OF ALLERGIC RHINITIS, ASTHMA |